Please assess the completion status of the following clinical trial:

Trial Title: Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/biopsy confirmed adenocarcinoma of prostate within 1 year of registration~* Disease confined to the prostate. Prostate volume must be \<150cc confirmed by pelvic CT (with or without contrast) or pelvic/prostate MRI (with or without contrast) +/- ultrasound, within 8 months of signing research consent~* Age \>18~* Patients deemed medically suitable to undergo rectal spacer placement, external beam radiotherapy and brachytherapy at the discretion of the radiation oncologist, urologist, medical oncologist and/or internist.~* ECOG score of 0-2.~* One or more of the following risk factors for intermediate risk prostate cancer; T2b or T2c clinical stage, GS 7 (either 3+4 or 4+3), PSA 10-20.~* Ability to understand and the willingness to sign a written informed consent.~* PSA result within 6 months of simulation~Exclusion Criteria:~* Patients with disease not confined to the prostate based on imaging, biopsy, or clinical exam~* Patients with a prostate size \> 100 cc based on computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound measurements~* Patients who have undergone previous rectal, bowel, bladder, or prostate surgeries in the past~* Patients with previous treatments for their prostate cancer or that are currently receiving any other experimental therapies~* Patients who have undergone prior pelvic radiotherapy~* Patients with high risk prostate cancer that have any of the following risk factors; GS \>= 8, PSA \> 20, clinical or imaging stage T3a or higher~* Patients receiving antiandrogen therapy (ADT)~* Patients with any prior active or treated genitourinary malignancy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with prostate cancer (Type: EXPERIMENTAL): Patients undergo hydrogel rectal spacer placement on day 1. Within 2 weeks (+/-1 week) after Rectal Spacer placement, patients will be scheduled for CT simulation for external beam treatment planning. Patients will begin the SBRT of 24Gy in 5 fractions within 2 weeks (+/-1 week) from the simulation date. Within 4 weeks (+/-1 week) of last day of SBRT, patients undergo brachytherapy. Patient will return for post-implant CT-based dosimetry analysis 4 weeks (+/- 1 week) post brachytherapy,

Based on this trial design, predict the completion outcome and termination type (if applicable).